DV
Dividend Vision

ARTL Stock — Artelo Biosciences Inc

Artelo Biosciences Inc (ARTL)

Updated November 9, 2026.

ARTL is a stock. Total return is -100.0% over the past 9 years, 335.2 points behind SPY at 235.2%.

Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapeutics targeting lipid-signaling pathways, with a pipeline that includes drug candidates for cancer-related anorexia, anxiety, depression, PTSD, epilepsy, insomnia, and various pain and neuropathy indications. The company does not currently distribute dividends. Early-stage biotech companies appeal primarily to growth-oriented investors willing to accept the risks associated with clinical development and regulatory uncertainty, rather than those seeking current income.

ARTL dividend yield and income

Price as of 2026-11-09.

The payment date is 06/21/2019.

ARTL performance versus SPY

Total return is -100.0% over the past 9 years, 335.2 points behind SPY at 235.2%. Over the past year its total return — price change plus distributions reinvested — is -96.5%. Its deepest 1-year drawdown was 98.0%.

WindowTotal returnCAGR
1M-36.5%—
3M-68.1%—
6M-90.9%—
YTD-93.7%—
1Y-96.5%—
2Y CAGR—-89.40%
3Y CAGR—-78.70%
5Y CAGR—-75.50%
Since inception 2017-11-14 · 9 years-100.0%-61.00%

ARTL key facts

Asset type
Stock
Asset class
Equity
Inception date
11/14/2017
Distribution frequency
None
Last close
$2.07 (as of 2026-11-09)
Market cap
$1,133,892
Average volume
46,183
Payment date
06/21/2019
Beta
-0.006
Payout ratio
0.0%
EPS
-$124.34

How Dividend Vision calculates returns

Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ARTL risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 98.0%.

Who may consider ARTL — and who may not

It is a weaker fit for investors who need monthly cash flow (ARTL does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ARTL

Tagged: Healthcare.

Frequently asked questions

Does ARTL pay monthly?

No. ARTL does not currently distribute.

When does ARTL pay a dividend?

ARTL does not currently distribute. The payment date is 06/21/2019.

How has ARTL performed?

Total return is -100.0% over the past 9 years, 335.2 points behind SPY at 235.2%. Over the past year its total return — price change plus distributions reinvested — is -96.5%. Its deepest 1-year drawdown was 98.0%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.